 SOUTH SAN FRANCISCO, July 01, 2021 GLOBE NEWSWIRE -- Tempest Therapeutics, Inc. Nasdaq: TPST Tempest, a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of 20-year industry veteran Christine Pellizzari to the companys Board of Directors. 